DNASE2 Deficiency (Autoinflammatory–Pancytopenia Syndrome, AIPCS): Comprehensive Disease Characteristics Report

Disease: DNASE2 Deficiency / Autoinflammatory–Pancytopenia Syndrome (AIPCS) MONDO: MONDO:0800132 · OMIM: #619858 · Category: Mendelian (autosomal recessive)

Evidence base: This is an ultra-rare disease with a small primary human literature (first described 2017). Mechanistic depth comes largely from mouse genetics, which recapitulate the human phenotype well. Evidence-source types are flagged throughout as [human], [mouse], [in vitro], or [computational].

Summary

DNASE2 deficiency — formally designated Autoinflammatory–Pancytopenia Syndrome (AIPCS; MONDO:0800132, OMIM #619858) — is an ultra-rare, autosomal-recessive monogenic type I interferonopathy caused by biallelic loss-of-function variants in DNASE2 (chromosome 19p13.13). The gene encodes DNase II-alpha, a 360-amino-acid ubiquitously expressed lysosomal acid endonuclease that degrades DNA derived from apoptotic cells and from nuclei expelled by erythroblasts during definitive erythropoiesis. When this enzyme is lost, undegraded self-DNA accumulates within macrophage lysosomes and leaks to the cytosol, where it is sensed by the TLR-independent cGAS–STING–TBK1–IRF3/7 axis. The result is constitutive overproduction of type I interferon (principally IFN-β), accompanied by a separable TNF-α–driven inflammatory program, which together produce a congenital/neonatal-onset multisystem autoinflammatory disease.

The core human phenotype, first defined by Rodero et al. in 2017, comprises severe neonatal anemia, membranoproliferative glomerulonephritis, liver fibrosis, deforming arthropathy, and anti-DNA antibodies, all on a background of a strong blood interferon signature and constitutive STAT1/STAT3 phosphorylation. Subsequent case reports have expanded the spectrum to include an extremely severe antenatal presentation (fetal hydrops, intrauterine growth restriction, cardiomyopathy, persistent pancytopenia, hepatosplenomegaly, cholestatic jaundice, and hemophagocytic lymphohistiocytosis–like features with marked hyperferritinemia), as well as recurrent fevers, vasculitic skin lesions/chilblains, gastrointestinal inflammation, lipodystrophy, and subcortical white-matter lesions.

The disease mechanism is exceptionally well validated by Dnase2-null mouse genetics: embryonic lethality from IFN-β–driven lethal anemia is rescued by crossing onto an Ifnar-null background, sensing is TLR-independent, and the surviving mice develop a chronic, TNF-α–dependent, rheumatoid-arthritis-like polyarthritis driven in part by IFN-γ–producing Th1 cells independent of type I IFN. Diagnosis rests on the blood interferon signature, reduced DNase II enzymatic activity, and exome/genome sequencing. Mechanism-directed treatment centers on JAK1/2 inhibitors (baricitinib, ruxolitinib) to suppress IFN signaling, with a strong preclinical rationale for anti-TNF therapy against the arthritis component and hematopoietic stem-cell transplantation as a conceptual cure.

Key Findings

F001 — DNASE2 deficiency is an autosomal-recessive type I interferonopathy caused by biallelic loss-of-function DNASE2 variants [human]

The defining human study is Rodero et al. (2017), which identified biallelic DNASE2 mutations in three patients from two families, each with loss of DNase II endonuclease activity, elevated IFN-alpha protein measured by digital ELISA, enhanced interferon signaling on RNA-Seq, and constitutive upregulation of phosphorylated STAT1 and STAT3 in patient lymphocytes and monocytes. In the authors' words: "In both families we identify biallelic mutations in DNASE2, associated with a loss of DNase II endonuclease activity. We record increased interferon alpha protein levels using digital ELISA, enhanced interferon signaling by RNA-Seq analysis and constitutive upregulation of phosphorylated STAT1 and STAT3 in patient lymphocytes and monocytes" PMID: 29259162. Subsequent reports confirmed additional biallelic/homozygous pathogenic variants, including a proximal intronic splice-site variant causing type I interferon-mediated autoinflammation in two unrelated patients PMID: 41472683, which describes DNase II as "a lysosomal endonuclease critical for degrading DNA during erythropoiesis and apoptosis" and confirms recessive biallelic loss-of-function inheritance. This establishes the disease as a monogenic, recessive interferonopathy with a clear molecular signature.

F002 — Core clinical phenotype: neonatal anemia, membranoproliferative glomerulonephritis, liver fibrosis, deforming arthropathy, and anti-DNA antibodies [human]

The index cohort variably demonstrated a stereotyped multisystem picture: "we identify two siblings and a singleton variably demonstrating severe neonatal anemia, membranoproliferative glomerulonephritis, liver fibrosis, deforming arthropathy and increased anti-DNA antibodies" PMID: 29259162. Peripheral blood showed increased erythroblasts and a hematological-disease transcriptomic signature, linking the anemia directly to the enzyme's erythropoietic role. The 2026 Omani neonatal report expanded the severe end of the spectrum, with disease "manifesting antenatally with fetal hydrops, intrauterine growth restriction, and cardiomyopathy. Postnatally, the infant developed persistent pancytopenia, hepatosplenomegaly, cholestatic jaundice, and hemophagocytic lymphohistiocytosis-like features, including marked hyperferritinemia" PMID: 42491852.

F003 — Mechanism: undegraded self-DNA drives cGAS–STING-dependent type I IFN, with an IFNAR-independent inflammatory branch [mouse, in vitro]

Mouse genetics establish an unambiguous causal chain. Dnase2-null embryos accumulate undigested DNA in macrophages and die in utero from IFN-β–driven lethal anemia; crucially, "When the DNase II-deficient mice were crossed with mice deficient in type I interferon receptor, the resultant 'double-mutant' mice were born healthy" PMID: 15568025, proving type I IFN signaling via IFNAR is causally required for lethal anemia. Sensing is TLR-independent: "The ablation of Toll-like receptor (TLR) 3 and 9, or their adaptor molecules (MyD88 and TRIF), had no effect on the lethality of the DNase II(-/-) mice. These results indicate that there is a TLR-independent sensing mechanism" PMID: 16301743, implicating cytosolic cGAS–STING. This is confirmed functionally: DNase2-deficient patient fibroblasts have a constitutively primed cGAS–STING–TBK1 pathway PMID: 33916318. A type I IFN-independent branch also contributes — in Dnase2/Ifnar double-knockout mice, chronic polyarthritis is driven by IFN-γ–producing Th1 cells PMID: 31464028 — and STING contributes to paradoxical ectopic bone formation PMID: 27740718.

F004 — DNase II acts non-cell-autonomously in macrophages to degrade erythroid-expelled nuclear DNA; it is essential for definitive erythropoiesis [mouse]

Kawane et al. (2001) showed that DNase II-null mice are not born, dying of severe anemia, and that transfer of mutant fetal liver cells into irradiated wild-type mice generated mature red blood cells, demonstrating a non-cell-autonomous mechanism. Histochemistry localized the critical enzyme source: "the critical cellular sources of DNase II are macrophages present at the site of definitive erythropoiesis in the fetal liver. Thus, DNase II in macrophages appears to be responsible for destroying the nuclear DNA expelled from erythroid precursor cells" PMID: 11375492. This directly explains the anemia: central nurse macrophages in erythroblastic islands normally phagocytose and digest the extruded erythroblast nucleus, and without DNase II this DNA accumulates and triggers IFN.

F005 — Two-branch mechanism: IRF3/7-dependent IFN-β drives embryonic anemia; TNF-α drives chronic polyarthritis (IFN-independent) [mouse]

Kawane et al. (2006) found that Dnase2⁻/⁻ Ifnar⁻/⁻ mice (and mice with induced DNase II deletion) develop chronic, destructive polyarthritis resembling rheumatoid arthritis, with high serum anti-CCP antibody, rheumatoid factor, and MMP-3. "Early in the pathogenesis, expression of the gene encoding tumour necrosis factor (TNF)-alpha was upregulated in the bone marrow, and administration of anti-TNF-alpha antibody prevented the development of arthritis" PMID: 17066036. Okabe et al. (2008) dissected the transcriptional logic: "DNase II(-/-)IRF3(-/-)IRF7(-/-) mice do not suffer from anemia, but they still produce TNF-alpha, and age-dependently develop chronic polyarthritis" PMID: 18991290. Thus two separable gene-induction programs flow from the same undegraded DNA: an IRF3/7-dependent IFN-β program (anemia) and an IRF3/7-independent TNF-α program (arthritis). HMGB-1 is an additional pathogenic mediator in the arthritis model, with HMGB-1 blockade ameliorating disease PMID: 20533288.

F006 — DNASE2 gene/protein: chromosome 19, a 360-aa ubiquitously expressed lysosomal acid endonuclease [human]

Yasuda et al. (1998) cloned the human DNase II cDNA: "an open reading frame of 1080 bases, which encoded a single polypeptide of 360 amino acids (signal peptide, 16; propeptide, 91; mature protein, 253)" and established that "DNase II is ubiquitously expressed in human tissues, and the DNase II gene (DNASE2) was assigned to chromosome 19" PMID: 9446563. The enzyme is an acid, divalent-cation-independent endonuclease active at lysosomal pH, with a cDNA organization resembling the lysosomal cathepsin families.

F007 — Treatment: JAK inhibitors as targeted therapy; anti-TNF rationale for arthritis; HSCT conceptually curative [human, mouse]

In the severe antenatal case, "Whole-exome sequencing enables definitive diagnosis, and Janus kinase inhibitors have emerged as targeted immunomodulatory therapy" PMID: 42491852. JAK1/2 inhibitors (baricitinib, ruxolitinib) reduce the interferon signature and systemic/dermatologic inflammation across type I interferonopathies, with greater benefit in mild/intermediate phenotypes and earlier initiation PMID: 41871482. The mouse arthritis branch is prevented by "administration of anti-TNF-alpha antibody" PMID: 17066036. Allogeneic HSCT achieved cure in the related interferonopathy SAVI PMID: 42137281, supporting a hematopoietic-targeted curative strategy since DNase II's critical role is in macrophages.

F008 — DNASE2 is loss-of-function tolerant in gnomAD, consistent with recessive inheritance and healthy carriers [computational]

gnomAD constraint metrics for DNASE2 (ENSG00000105612) indicate tolerance of heterozygous loss of function: pLI ≈ 1.5×10⁻⁸ (effectively 0), observed/expected LoF = 0.87 (90% CI 0.64–1.21), lof_z = 0.59, mis_z = 0.81. This is exactly the constraint signature expected of a recessive disease gene where carriers are unaffected. Verified identifiers (via mygene.info): HGNC:2960, Entrez 1777, Ensembl ENSG00000105612, locus 19p13.13, UniProt O00115; mouse ortholog Dnase2a (Entrez 13423, MGI:1329019).

F009 — Authoritative identifiers and ontology annotations [computational]

EBI OLS4 gives MONDO:0800132 the official label "autoinflammatory-pancytopenia syndrome due to DNASE2 deficiency," with cross-references OMIM:619858 (phenotype), UMLS:C5676977, and MedGen:1803642. The gene alias "AIPCS" is the phenotype acronym (Autoinflammatory–Pancytopenia Syndrome). UniProt O00115 GO annotations include GO:0004531 (deoxyribonuclease II activity, molecular function), GO:0006309 (apoptotic DNA fragmentation), GO:0043277 (apoptotic cell clearance), GO:0005764 (lysosome), and GO:0070062 (extracellular exosome). The catalytic activity is endonucleolytic cleavage to nucleoside 3′-phosphate / 3′-phospho-oligonucleotide products; the enzyme is an acidic-pH dsDNA-preferring hydrolase necessary for definitive erythropoiesis.

F010 — Authoritative HPO phenotype spectrum expands features beyond the index report [human]

The JAX HPO annotation of OMIM:619858 (MONDO:0800132) catalogs a broad spectrum: severe anemia (HP:0001903), thrombocytopenia (HP:0001873), pancytopenia (HP:0001876), hemophagocytosis (HP:0012156), hepatosplenomegaly (HP:0001433), hepatic fibrosis (HP:0001395), cholestatic liver disease (HP:0002611), membranoproliferative glomerulonephritis (HP:0000793), proteinuria (HP:0000093), arthropathy (HP:0003040), recurrent fever/fever (HP:0001954/HP:0001945), chilblains (HP:0009710), granuloma (HP:0032252), chronic diarrhea (HP:0002028), intestinal inflammation (HP:4000055), failure to thrive/growth delay (HP:0001508/HP:0001510), motor delay (HP:0001270/HP:0002194), lipodystrophy (HP:0009125), type 1 diabetes (HP:0100651), and severe EBV infection (HP:0031693). Onset is congenital (HP:0003577)/neonatal (HP:0003623); inheritance is autosomal recessive (HP:0000007). The OMIM description additionally notes vasculitic skin lesions and subcortical white-matter lesions on brain imaging.

Section-by-Section Report

1. Disease Information

Overview. DNASE2 deficiency is a monogenic autosomal-recessive systemic autoinflammatory disorder classified as a type I interferonopathy. Loss of the lysosomal enzyme DNase II leads to accumulation of undegraded self-DNA, chronic type I interferon production, and multisystem inflammation beginning before or at birth.

Key identifiers.

Resource Identifier
MONDO MONDO:0800132 ("autoinflammatory-pancytopenia syndrome due to DNASE2 deficiency")
OMIM (phenotype) #619858
UMLS C5676977
MedGen 1803642
Gene (HGNC) DNASE2, HGNC:2960
Entrez Gene 1777
Ensembl ENSG00000105612
UniProt O00115
Orphanet Not established as a distinct ORPHA code at time of research (ultra-rare; <10 reported families)
ICD-10/ICD-11 No specific code; falls under autoinflammatory/immunodeficiency groupings
MeSH No dedicated descriptor; indexed via DNASE2 and "interferon type I"

Synonyms / alternative names: AIPCS; Autoinflammatory–Pancytopenia Syndrome; DNase II deficiency; DNase II-alpha deficiency; type I interferon-mediated autoinflammation due to DNase II deficiency.

Information source: Disease-level knowledge is derived from a small number of individual patient reports (aggregated into OMIM/MONDO/HPO disease-level resources) plus extensive Dnase2-null mouse model data. This is not EHR/population-derived; it is individual-patient and model-organism derived.

2. Etiology

Causal factors. The disease is purely genetic: biallelic (homozygous or compound heterozygous) loss-of-function variants in DNASE2 PMID: 29259162. There is no infectious or primary environmental cause.

Genetic risk factors. The only established risk factor is inheritance of two loss-of-function DNASE2 alleles. DNASE2 is LoF-tolerant in gnomAD (pLI ≈ 0, LOEUF upper bound 1.21), so heterozygous carriers are healthy (F008). Consanguinity increases risk of homozygosity, as expected for any ultra-rare recessive disorder; several reported cases are from consanguineous or isolated-population backgrounds (e.g., the Omani neonate, PMID: 42491852).

Environmental risk / protective factors. None established. As a Mendelian monogenic disorder, environmental exposures are not primary determinants. Mechanistically, a bacterial/LPS (TLR4) stimulus can amplify IFN output in cells with a primed cGAS–STING pathway PMID: 33916318, suggesting infections could trigger flares, but this is inferred rather than demonstrated clinically.

Protective genetic factors. In mice, loss of IFNAR, STING, or IRF3/7 rescues or attenuates disease — these are experimental "protective" modifiers establishing the pathway, not naturally occurring human protective alleles (F003, F005).

Gene–environment interactions. Not formally characterized in humans. The cGAS–STING priming data (PMID: 33916318) imply plausible interaction between the genetic lesion and microbial/LPS exposure, but this remains hypothetical.

3. Phenotypes

The phenotype is congenital/neonatal-onset, severe, progressive, and multisystem. Frequencies are qualitative given the ultra-rare cohort (fewer than ~10 reported patients).

Phenotype HPO term Type Onset Severity Notes
Severe anemia HP:0001903 Lab/clinical Neonatal/antenatal Severe Core feature; from failed erythroblast DNA clearance
Thrombocytopenia HP:0001873 Lab Neonatal Moderate–severe Part of pancytopenia
Pancytopenia HP:0001876 Lab Neonatal Severe Severe spectrum
Hemophagocytosis / HLH-like HP:0012156 Lab/clinical Neonatal Severe With hyperferritinemia (P42491852)
Hepatosplenomegaly HP:0001433 Clinical sign Neonatal Moderate–severe
Hepatic fibrosis HP:0001395 Pathology Infancy Progressive
Cholestatic liver disease HP:0002611 Lab/clinical Neonatal Variable
Membranoproliferative glomerulonephritis HP:0000793 Pathology Childhood Progressive With proteinuria (HP:0000093)
Deforming arthropathy HP:0003040 Clinical sign Childhood Progressive, deforming TNF-driven branch
Recurrent fever HP:0001954 / HP:0001945 Symptom Early Episodic Autoinflammatory
Chilblains / vasculitic skin lesions HP:0009710 Physical Early Variable Interferonopathy skin signature
Granuloma HP:0032252 Pathology Variable —
Intestinal inflammation / chronic diarrhea HP:4000055 / HP:0002028 Clinical Early Variable
Failure to thrive / growth delay HP:0001508 / HP:0001510 Clinical Infancy Variable
Motor delay HP:0001270 / HP:0002194 Neurodevelopmental Infancy Variable
Lipodystrophy HP:0009125 Physical Variable — Shared with other interferonopathies
Type 1 diabetes HP:0100651 Lab/clinical Variable —
Severe EBV infection HP:0031693 Clinical Variable —
Subcortical white-matter lesions (imaging) Imaging Variable — Per OMIM description
Increased anti-DNA antibodies — Lab Childhood — Lupus-like autoimmunity

Quality-of-life impact: Given congenital onset, severe anemia/pancytopenia, progressive organ fibrosis, and deforming arthropathy, affected children have substantial functional impairment and dependence on transfusion and immunomodulation. No disease-specific EQ-5D/SF-36/PROMIS data exist for this ultra-rare condition.

4. Genetic/Molecular Information

Causal gene: DNASE2 (DNase II-alpha), HGNC:2960, Entrez 1777, Ensembl ENSG00000105612, UniProt O00115, locus 19p13.13; phenotype OMIM #619858.

Pathogenic variants. Biallelic loss-of-function variants cause disease. Reported types include missense variants abolishing endonuclease activity (index families, PMID: 29259162), a novel DNASE2 mutation in a severe antenatal case (PMID: 42491852), and a proximal intronic splice-site variant in two unrelated patients (PMID: 41472683). Under ACMG/AMP criteria, disease-causing alleles are classified pathogenic/likely pathogenic when they ablate DNase II enzymatic activity. Functional consequence: loss of function (reduced/absent acid DNase II activity). Origin is germline; no somatic/cancer association. Population allele frequencies for pathogenic alleles are extremely low (ultra-rare), consistent with gnomAD LoF tolerance for carriers (F008).

Modifier genes. No human modifiers confirmed. In mice, the pathway genes Ifnar1, Sting1 (Tmem173), Irf3, and Irf7 act as powerful genetic modifiers of outcome (anemia vs arthritis vs rescue; F003/F005).

Epigenetics / chromosomal abnormalities. Not implicated; the disease is a single-gene disorder with no reported large-scale structural or epigenetic lesions.

5. Environmental Information

No environmental toxins, radiation, lifestyle factors, or infectious agents are established as causes. The disease is monogenic. The only mechanistically plausible environmental modulator is microbial/LPS stimulation amplifying IFN in cGAS–STING-primed cells (PMID: 33916318) — potentially relevant to flares but unproven clinically. Severe EBV infection (HP:0031693) appears in the HPO spectrum, which may reflect secondary infection susceptibility rather than a trigger.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

  1. Biallelic loss-of-function DNASE2 variants result in absent/severely reduced lysosomal acid DNase II activity (F001, F006).
  2. Loss of DNase II leads to failure to degrade DNA delivered to macrophage lysosomes — specifically the nuclei expelled by erythroblasts during definitive erythropoiesis and DNA from engulfed apoptotic cells (F004).
  3. Undegraded self-DNA accumulates in macrophage lysosomes and leaks into the cytosol (inferred from priming data; F003).
  4. Cytosolic self-DNA activates the TLR-independent cGAS–STING–TBK1 sensing pathway (F003; TLR-independence demonstrated, PMID: 16301743).
  5. Branch A (IRF3/7-dependent): TBK1 activates IRF3/IRF7 → transcription of IFN-β → autocrine/paracrine IFNAR signaling → JAK–STAT1/STAT3 phosphorylation → interferon-stimulated gene program. In the embryo this causes lethal anemia; rescued by IFNAR loss (F003, F005).
  6. Branch B (IRF3/7-independent): the same DNA induces TNF-α (and HMGB-1) independent of IRF3/7 and type I IFN → chronic deforming polyarthritis; prevented by anti-TNF, and in Ifnar-null mice driven further by IFN-γ–producing Th1 cells (F005; PMID: 17066036, PMID: 18991290, PMID: 31464028).
  7. Sustained IFN/TNF/IFN-γ signaling produces the human multisystem disease: anemia/pancytopenia, HLH-like macrophage activation, liver fibrosis, membranoproliferative glomerulonephritis, vasculitic skin disease, GI inflammation, and anti-DNA autoimmunity (F002, F010).
  8. A STING-dependent side-branch contributes to paradoxical ectopic bone formation at sites of DNA accrual (F003; PMID: 27740718).
 DNASE2 LoF (lysosome)
        │ no DNA degradation
        ▼
 Undegraded self-DNA in macrophages  ── UBERON: fetal liver, bone marrow
        │ cytosolic leak
        ▼
 cGAS ─► STING ─► TBK1   (TLR-independent)
        │                         │
   IRF3/7 dependent          IRF3/7 independent
        │                         │
      IFN-β ─► IFNAR          TNF-α / HMGB-1 ─► (Th1/IFN-γ)
        │ JAK-STAT1/3             │
   ANEMIA, IFN signature      CHRONIC ARTHRITIS
   (rescued by Ifnar-/-)      (blocked by anti-TNF)

Molecular pathways: cGAS–STING cytosolic DNA sensing; type I IFN / JAK–STAT; TNF-α signaling (KEGG/Reactome: "Cytosolic DNA-sensing pathway," "Interferon alpha/beta signaling").

Cellular processes: apoptotic DNA fragmentation (GO:0006309), apoptotic cell clearance (GO:0043277), definitive erythropoiesis, macrophage-mediated phagocytosis, chronic inflammation, autoinflammation.

Protein dysfunction: loss of deoxyribonuclease II activity (GO:0004531); the catalytic endonuclease fails to cleave dsDNA to 3′-phosphate products.

Immune system involvement: combined innate autoinflammation (IFN-β, TNF-α) and adaptive autoimmunity (anti-DNA antibodies, Th1/IFN-γ, anti-CCP/RF in the murine model).

Cell types (CL): macrophage (CL:0000235), erythroblast/erythroid precursor (CL:0000765), monocyte (CL:0000576), T-helper 1 cell (CL:0000545).

Subcellular compartment (GO CC): lysosome (GO:0005764); cytosol (site of cGAS sensing); extracellular exosome (GO:0070062).

Molecular profiling: patient RNA-Seq shows an enhanced interferon signature; blood IFN signatures (6-gene ISG panels) are measurable by RT-qPCR/Nanostring PMID: 30413290; proteomic ISG signatures (IFIT5, ISG15, OAS2) are detectable even in neonatal dried blood spots PMID: 40319946.

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Interpretation

The pathophysiology of DNASE2 deficiency is one of the most cleanly resolved causal chains among the interferonopathies, because mouse genetics have epistatically ordered every step. The single initiating lesion — loss of lysosomal DNase II — removes the terminal nuclease that macrophages use to digest two major streams of self-DNA: the nuclei that erythroblasts expel during definitive erythropoiesis, and the chromatin of apoptotic cells they engulf. The undigested DNA becomes a danger signal. Because sensing is demonstrably TLR-independent and because it is abolished by removing STING-pathway components, the responsible sensor is cytosolic cGAS feeding STING–TBK1. From TBK1 the signal bifurcates: an IRF3/7-dependent arm makes IFN-β (producing the lethal fetal anemia and the human IFN signature), and an IRF3/7-independent arm makes TNF-α (and HMGB-1), producing the chronic deforming arthritis. A third, IFN-independent adaptive arm (IFN-γ–producing Th1 cells) amplifies the arthritis once type I IFN is removed.

This branched architecture directly rationalizes therapy. JAK inhibitors intercept the IFNAR→JAK–STAT limb and should dampen the IFN-driven systemic and hematologic/skin disease; anti-TNF should specifically address the arthritis limb; and HSCT, by replacing the macrophage compartment with DNase II-competent cells, addresses the lesion at its cellular source. The gnomAD constraint data close the loop on genetics: DNASE2 tolerates heterozygous loss of function, exactly as required for a recessive disease whose carriers are healthy.

Mechanistic step Position Key evidence Source
DNASE2 LoF → no lysosomal DNA digestion Upstream (initiating) 29259162, 9446563 human
Macrophage accumulation of erythroid/apoptotic DNA Upstream 11375492 mouse
TLR-independent cytosolic sensing (cGAS-STING-TBK1) Midstream 16301743, 33916318 mouse, in vitro
IRF3/7 → IFN-β → IFNAR → anemia Downstream (branch A) 15568025, 18991290 mouse
IRF3/7-independent TNF-α → arthritis Downstream (branch B) 17066036, 18991290 mouse
IFN-γ/Th1 amplification of arthritis Downstream 31464028 mouse
Human multisystem disease Terminal 29259162, 42491852 human

Evidence Base

PMID Role Contribution
29259162 Defining human study Biallelic DNASE2 LoF; IFN signature; core phenotype (F001, F002)
41472683 Human case series Intronic splice variant; confirms recessive LoF; lysosomal role (F001)
42491852 Human case report Severe antenatal spectrum; WES diagnosis; JAK inhibitors (F002, F007)
11375492 Mouse DNase II macrophage non-cell-autonomous role in erythropoiesis (F004)
15568025 Mouse genetics IFN-β/IFNAR causally required for lethal anemia (F003)
16301743 Mouse genetics TLR-independent self-DNA sensing → cGAS-STING (F003)
33916318 Patient cells Constitutively primed cGAS-STING-TBK1 in DNase2-deficient fibroblasts (F003)
17066036 Mouse TNF-α drives arthritis; anti-TNF protective (F005, F007)
18991290 Mouse genetics IRF3/7-dependent (anemia) vs independent (TNF/arthritis) branches (F005)
31464028 Mouse IFN-γ/Th1 drives type I IFN-independent arthritis (F003)
27740718 Mouse STING required for ectopic bone formation (F003)
20533288 Mouse HMGB-1 pathogenic in the arthritis model; blockade ameliorates
9446563 Molecular DNASE2 cloning; 360-aa protein; chr 19; ubiquitous expression (F006)
30413290 Diagnostic 6-gene IFN signature (RT-qPCR/Nanostring) for interferonopathies
40319946 Diagnostic Neonatal DBS proteomic IFN signature (IFIT5, ISG15, OAS2)
41871482 Treatment JAK1/2 inhibitor efficacy in interferonopathies (F007)
42137281 Treatment Allo-HSCT cured SAVI — rationale for HSCT (F007)
40176112 Treatment Tofacitinib for interferonopathy skin lesions

Limitations and Knowledge Gaps

Proposed Follow-up Experiments / Actions

  1. Establish an international AIPCS patient registry to aggregate genotype, phenotype, IFN-signature, treatment response, and survival data across the few families worldwide.
  2. Prospective JAK-inhibitor outcome study (baricitinib/ruxolitinib) in confirmed DNASE2-deficiency patients, tracking IFN signature, transfusion requirement, hepatic/renal function, and arthropathy, with early vs late initiation comparison.
  3. Formal genotype–function correlation: quantify residual DNase II activity for each reported variant (including the intronic splice allele) and relate to clinical severity along the antenatal-lethal → childhood-arthropathy spectrum.
  4. Direct in-patient cGAS–STING engagement assays (e.g., cGAMP measurement, STING oligomerization) to confirm the inferred cytosolic-leak step in humans.
  5. Evaluate upstream pathway inhibitors (cGAS or STING antagonists) in patient cells and Dnase2-null models as alternatives/adjuncts to JAK inhibition.
  6. Pilot/registry data on HSCT for severe, refractory DNASE2 deficiency, given the macrophage-restricted critical function and the SAVI precedent.
  7. Validate neonatal DBS IFN-proteomic screening prospectively in at-risk (consanguineous) pregnancies for presymptomatic detection and early intervention.

Report compiled from 10 confirmed findings and 22 reviewed papers across 5 investigation iterations. Evidence types are distinguished throughout as human clinical, model organism (mouse), in vitro (patient cells), or computational (gnomAD/ontology).